Suppr超能文献

门静脉海绵样变胆管病的内镜治疗:实践、原则与策略

Endoscopic management of portal cavernoma cholangiopathy: practice, principles and strategy.

作者信息

Saraswat Vivek A, Rai Praveer, Kumar Tarun, Mohindra Samir, Dhiman Radha K

机构信息

Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh 226014, India.

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.

出版信息

J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S67-76. doi: 10.1016/j.jceh.2013.08.011. Epub 2013 Oct 22.

Abstract

Portal cavernoma cholangiopathy (PCC) is the presence of typical cholangiographic changes in patients with a portal cavernoma due to chronic portal vein thrombosis, in the absence of other biliary tract diseases. Probably due to biliary stasis related to the cavernoma, there is a high incidence of biliary sludge and calculi in PCC, which trigger symptoms that resolve with appropriate interventions. Persistent and troublesome symptoms are usually due to biliary stenoses or strictures, which may occur with or without biliary calculi and may be short or long, solitary or multifocal, extrahepatic or intrahepatic. Experience with endoscopic interventions in PCC over the last twenty years has shown that it is the procedure of choice for bile duct calculi. Plastic stenting with repeated, timely, stent exchanges is the first line intervention for jaundice or cholangitis due to biliary strictures. If biliary obstruction does not resolve, portosystemic shunt surgery (PSS) or transjugular intrahepatic portosystemic stent shunt (TIPS) is performed to decompress the portal cavernoma. However, for patients with non-shuntable veins or blocked shunts, repeated plastic stent exchanges are the only option though there are reports of the use of biliary self-expandable metal stents in this situation. If symptomatic biliary obstruction persists after successful PSS or TIPS, second stage biliary surgery may be necessary. Recent experience suggests that treating biliary strictures in PCC on the lines of postoperative benign biliary strictures with balloon dilatation and repeated exchanges of plastic stent bundles may be effective therapy. Endoscopic management appears to be associated with an increased frequency of hemobilia, which usually responds to standard management. Recurrent cholangitis with formation of sludge and concretions may be a problem with repeated stent exchanges, especially if patient compliance is poor. In conclusion, the current understanding is that symptomatic PCC is best managed jointly by the endoscopist and surgeon with sequential interventions designed initially to establish and maintain biliary drainage, then to decompress the portal cavernoma and, finally, if required, second stage biliary surgery or endotherapy for biliary strictures. Endoscopic therapy occupies a central role in management before, during and after surgical therapy. Paradigms of endoscopic therapy continue to evolve as knowledge of pathogenesis and natural history improves and newer approaches and techniques are applied.

摘要

门静脉海绵样变胆管病(PCC)是指因慢性门静脉血栓形成导致门静脉海绵样变的患者出现典型的胆管造影改变,且无其他胆道疾病。可能由于与海绵样变相关的胆汁淤积,PCC患者胆汁淤积和结石的发生率较高,这些可引发经适当干预后可缓解的症状。持续且棘手的症状通常归因于胆管狭窄,其可伴有或不伴有胆结石,可为短或长、单发或多发、肝外或肝内。过去二十年的PCC内镜干预经验表明,内镜是治疗胆管结石的首选方法。对于因胆管狭窄导致的黄疸或胆管炎,反复及时更换塑料支架进行支架置入是一线干预措施。如果胆道梗阻未缓解,则进行门体分流手术(PSS)或经颈静脉肝内门体分流术(TIPS)以减轻门静脉海绵样变的压力。然而,对于静脉不可分流或分流受阻的患者,尽管有在这种情况下使用胆道自膨式金属支架的报道,但反复更换塑料支架是唯一选择。如果在成功进行PSS或TIPS后仍存在有症状的胆道梗阻,则可能需要二期胆道手术。最近的经验表明,按照术后良性胆管狭窄的治疗方法,采用球囊扩张和反复更换塑料支架束来治疗PCC中的胆管狭窄可能是有效的治疗方法。内镜治疗似乎与胆道出血频率增加有关,胆道出血通常对标准治疗有反应。反复更换支架可能会出现复发性胆管炎并形成胆汁淤积和结石,尤其是在患者依从性差的情况下。总之,目前的认识是,有症状的PCC最好由内镜医师和外科医生联合管理,采取序贯干预措施,最初旨在建立和维持胆汁引流,然后减轻门静脉海绵样变的压力,最后,如果需要,进行二期胆道手术或针对胆管狭窄的内镜治疗。内镜治疗在手术治疗前、手术期间和手术后的管理中占据核心地位。随着对发病机制和自然史的认识提高以及应用更新的方法和技术,内镜治疗模式也在不断演变。

相似文献

1
Endoscopic management of portal cavernoma cholangiopathy: practice, principles and strategy.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S67-76. doi: 10.1016/j.jceh.2013.08.011. Epub 2013 Oct 22.
3
Surgical management of portal cavernoma cholangiopathy.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S77-84. doi: 10.1016/j.jceh.2013.07.005. Epub 2013 Sep 17.
4
Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S2-S14. doi: 10.1016/j.jceh.2014.02.003. Epub 2014 Feb 25.
5
Portal biliopathy.
World J Gastroenterol. 2016 Sep 21;22(35):7973-82. doi: 10.3748/wjg.v22.i35.7973.
8
Portal cavernoma cholangiopathy-clinical characteristics.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S34-6. doi: 10.1016/j.jceh.2013.05.014. Epub 2013 Oct 22.
9
Imaging of portal cavernoma cholangiopathy.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S44-52. doi: 10.1016/j.jceh.2013.07.004. Epub 2013 Sep 27.
10
Therapeutic approaches for portal biliopathy: A systematic review.
World J Gastroenterol. 2016 Dec 7;22(45):9909-9920. doi: 10.3748/wjg.v22.i45.9909.

引用本文的文献

1
Portal cavernoma cholangiopathy treated with living donor liver transplantation: a case report and review of the literature.
Clin J Gastroenterol. 2024 Dec;17(6):1080-1086. doi: 10.1007/s12328-024-02041-7. Epub 2024 Sep 23.
3
Rapidly Progressive Portal Cavernoma Cholangiopathy in a Patient With Infeasible Decompressive Shunt Surgery.
ACG Case Rep J. 2023 Jul 26;10(7):e00778. doi: 10.14309/crj.0000000000000778. eCollection 2023 Jul.
5
Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein.
Front Med (Lausanne). 2022 Mar 24;9:853138. doi: 10.3389/fmed.2022.853138. eCollection 2022.
6
Hemobilia: Perspective and Role of the Advanced Endoscopist.
Gastroenterol Res Pract. 2018 Jul 12;2018:3670739. doi: 10.1155/2018/3670739. eCollection 2018.
7
Pseudocholangiocarcinoma Sign: Management of Portal Cavernoma Biliopathy with Fully-Covered Self-Expandable Metal Stent.
Clin Endosc. 2017 May;50(3):305-307. doi: 10.5946/ce.2016.108. Epub 2017 Jan 26.
8
Primary Tubercular Liver Abscess Complicated by Tubercular Meningitis in Portal Cavernoma Cholangiopathy.
ACG Case Rep J. 2016 Dec 21;3(4):e196. doi: 10.14309/crj.2016.169. eCollection 2016 Aug.
9
Therapeutic approaches for portal biliopathy: A systematic review.
World J Gastroenterol. 2016 Dec 7;22(45):9909-9920. doi: 10.3748/wjg.v22.i45.9909.
10
Portal biliopathy.
World J Gastroenterol. 2016 Sep 21;22(35):7973-82. doi: 10.3748/wjg.v22.i35.7973.

本文引用的文献

1
Natural history of portal cavernoma cholangiopathy.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S62-6. doi: 10.1016/j.jceh.2013.08.003. Epub 2013 Aug 27.
2
Portal cavernoma cholangiopathy-clinical characteristics.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S34-6. doi: 10.1016/j.jceh.2013.05.014. Epub 2013 Oct 22.
3
Portal cavernoma cholangiopathy - history, definition and nomenclature.
J Clin Exp Hepatol. 2014 Feb;4(Suppl 1):S15-7. doi: 10.1016/j.jceh.2013.04.001. Epub 2013 Apr 17.
4
Portal biliopathy in patients with non-cirrhotic portal hypertension: does the type of surgery affect outcome?
HPB (Oxford). 2012 Jul;14(7):441-7. doi: 10.1111/j.1477-2574.2012.00473.x. Epub 2012 May 3.
5
Portal cholangiopathy: radiological classification and natural history.
Gut. 2011 Jun;60(6):853-60. doi: 10.1136/gut.2010.230201. Epub 2011 Jan 26.
6
Portal biliopathy: a study of 39 surgically treated patients.
HPB (Oxford). 2011 Jan;13(1):33-9. doi: 10.1111/j.1477-2574.2010.00232.x.
8
Endotherapy of postoperative biliary strictures with multiple stents: results after more than 10 years of follow-up.
Gastrointest Endosc. 2010 Sep;72(3):551-7. doi: 10.1016/j.gie.2010.04.052. Epub 2010 Jul 13.
9
Balloon sweep in portal biliopathy.
Gastrointest Endosc. 2010 Apr;71(4):885-6; author reply 886. doi: 10.1016/j.gie.2009.08.014.
10
Portal biliopathy in a 13-year-old Asian girl: a case report and review of literature.
Ann Afr Med. 2009 Jul-Sep;8(3):185-8. doi: 10.4103/1596-3519.57244.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验